Kezar Life Sciences is a clinical-stage biotechnology company, discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Co.'s primary product candidate, KZR-616, is a selective immunoproteasome inhibitor. KZR-261 is the main clinical candidate from Co.'s research platform targeting the Sec61 translocon and the protein secretion pathway for the discovery and development of small molecule therapeutics for oncology and autoimmune indications. KZR-261 has demonstrated anti-tumor activity in preclinical models of both solid and hematologic malignancies by targeting multiple pathways driving tumor growth and survival. We show 23 historical shares outstanding datapoints in our KZR shares outstanding history coverage, used to compute KZR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KZR market cap history over the course of time is important for investors
interested in comparing KZR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KZR versus a peer is one thing; comparing
KZR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KZR can fluctuate over the course of history.
With this page we aim to empower investors researching KZR by allowing them to research the KZR market cap history. |
Free KZR Email Alerts:
Video: The Importance of Market Cap
